Skip to content
RDL
Network
Ecosystem
Switch app
TR
About
FAQ
Sign in
Get started
Hepatic Arterial Infusion Chemotherapy versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma — Kazuomi Ueshima (2020) | RDL Network
Back
Cite
Save
Save for later
Share
Home
Publications
Hepatic Arterial Infusion Chemotherapy versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma
Shared by
Masatoshi Kudo
Hepatic Arterial Infusion Chemotherapy versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma
Article
2020
en
Authors
+19 more
KU
Kazuomi Ueshima
SO
Sadahisa Ogasawara
MI
Masafumi Ikeda
Abstract
1 min read
HAIC is a potential front-line treatment choice in a subpopulation of patients with advanced HCC with MVI but without EHM.
Discussion
(0)
Sign in
to like and join the discussion.
No comments yet. Be the first to comment.
Related publications
Dataset
Supplementary Material for: Hepatic Arterial Infusion Chemotherapy versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma
Kazuomi Ueshima
,
Sadahisa Ogasawara
,
Masafumi Ikeda
,
Y. Yasui
,
Takeshi Terashima
,
T. Yamashita
,
Shuntaro Obi
,
Shunsuke Sato
,
Hiroshi Aikata
,
Takumi Ohmura
,
Hidekatsu Kuroda
,
Takamasa Ohki
,
Kazutaka Nagashima
,
Yoshihiko Ooka
,
Mashiro Takita
,
Mami Kurosaki
,
Kazuaki Chayama
,
Shuichi Kaneko
,
Namiki Izumi
,
Naoya Kato
,
Masatoshi Kudo
,
Masao Omata
Article
2019
Sorafenib versus hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma: A Japanese multi-center large cohort study.
Sadahisa Ogasawara
,
Kazuomi Ueshima
,
Masafumi Ikeda
,
Yutaka Yasui
,
Takeshi Terashima
,
Tatsuya Yamashita
,
Shuntaro Obi
,
Shinpei Sato
,
Hiroshi Aikata
,
Takumi Ohmura
,
Hidekatsu Kuroda
,
Takamasa Ohki
,
Kengo Nagashima
,
Masayuki Kurosaki
,
Kazuaki Chayama
,
Shuichi Kaneko
,
Namiki Izumi
,
Naoya Kato
,
Masatoshi Kudo
,
Masao Omata
Dataset
Supplementary Material for: Multicenter Phase II trial of lenvatinib plus hepatic intra-arterial infusion chemotherapy with cisplatin for advanced hepatocellular carcinoma: LEOPARD
Masafumi Ikeda
,
Tatsuya Yamashita
,
Sadahisa Ogasawara
,
Masatoshi Kudo
,
Yoshitaka Inaba
,
Manabu Morimoto
,
Kaoru Tsuchiya
,
Shinichi Shimizu
,
Yasushi Kojima
,
Atsushi Hiraoka
,
Kazuhiro Nouso
,
Hiroshi Aikata
,
Kazushi Numata
,
Tosiya Sato
,
Takuji Okusaka
,
Junji Furuse
Article
2023
Multicenter Phase II Trial of Lenvatinib plus Hepatic Intra-Arterial Infusion Chemotherapy with Cisplatin for Advanced Hepatocellular Carcinoma: LEOPARD
Masafumi Ikeda
,
Tatsuya Yamashita
,
Sadahisa Ogasawara
,
Masatoshi Kudo
,
Yoshitaka Inaba
,
Manabu Morimoto
,
Kaoru Tsuchiya
,
Satoshi Shimizu
,
Yasushi Kojima
,
Atsushi Hiraoka
,
Kazuhiro Nouso
,
Hiroshi Aikata
,
Kazushi Numata
,
Tosiya Sato
,
Takuji Okusaka
,
Junji Furuse
Article
2008
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma and vascular invasion or extrahepatic spread: A subanalysis from the SHARP trial
Morris Sherman
,
Vincenzo Mazzaferro
,
D. Amadori
,
Julia Seitz
,
M. Moscovici
,
Ming Shan
,
Andrea Nadel
,
D. Voliotis
,
Josep M. Llovet
,
Jordi Bruix
Journal of Clinical Oncology
Discussion(0)
No comments yet. Be the first to comment.